Related Experiment Videos
IL-18-induced CD83+CCR7+ NK helper cells
Robbie B Mailliard1, Sean M Alber, Hongmei Shen
1Department of Surgery, University of Pittsburgh, PA, USA.
The Journal of Experimental Medicine
|October 6, 2005
Summary
Natural killer (NK) cells have a distinct "helper" pathway promoting immune responses, independent of their cytotoxic functions. Interleukin-18 (IL-18) induces this pathway, while prostaglandin E2 (PGE2) blocks it.
Area of Science:
- Immunology
- Cell Biology
Background:
- Natural killer (NK) cells possess both cytotoxic and immunoregulatory functions.
- Understanding NK cell differentiation pathways is crucial for immune modulation.
Purpose of the Study:
- To identify and characterize a distinct "helper" differentiation pathway in human NK cells.
- To elucidate the regulatory mechanisms, including specific cytokines and prostaglandins, involved in NK cell differentiation.
Main Methods:
- Flow cytometry was used to identify distinct NK cell populations (CD56+, CD3-, CD83+, CCR7+, CD25+).
- Functional assays assessed migratory responsiveness, cytokine production (interferon-gamma), and dendritic cell (DC) co-stimulation.
- Investigated the role of interleukin-18 (IL-18) and prostaglandin E2 (PGE2) in regulating NK cell differentiation.
Main Results:
- A novel NK cell helper pathway was identified, characterized by CD83+, CCR7+, and CD25+ expression, with enhanced migration to lymph nodes (LNs).
- These helper NK cells produced high levels of interferon-gamma and promoted T helper 1 (Th1) responses and interleukin (IL)-12p70 production in DCs.
- IL-18 induced this pathway, whereas PGE2 inhibited it, suggesting independent regulation of helper and effector functions.
Conclusions:
- NK cells differentiate into distinct helper subsets with potent immunoregulatory capabilities.
- IL-18 and PGE2 act as key regulators, independently controlling NK cell helper versus effector differentiation pathways.
- This discovery offers novel insights into NK cell-mediated immunoregulation and potential therapeutic targets.